- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07591493
Adjuvant Trial in Pancreatic Neuroendocrine Tumors (ADJUPANET)
First Adjuvant Trial in Locally Resected Aggressive Pancreatic Neuroendocrine Tumors: a Randomized Phase III Investigating the Efficacy of Systemic Chemotherapy
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Eric BAUDIN, MD
- Numéro de téléphone: 33 01 42 11 42 44
- E-mail: Eric.BAUDIN@gustaveroussy.fr
Sauvegarde des contacts de l'étude
- Nom: Matthieu FARON, MD
- Numéro de téléphone: 33 01 42 11 65 79
- E-mail: Matthieu.FARON@gustaveroussy.fr
Lieux d'étude
-
-
Île-de-France Region
-
Villejuif, Île-de-France Region, France, 94800
- Gustave Roussy
-
Contact:
- Matthieu FARON, MD
- Numéro de téléphone: +33 01 42 11 65 79
- E-mail: Matthieu.FARON@gustaveroussy.fr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Pathologically proven well differentiated neuro-endocrine tumour of the pancreas by local teams
- Availability of the primary tumor specimen, allowing accurate WHO classification and determination of MGMT status
- Stage I-III based ENETS-UICC 8th classification
- Early postoperative context (≤ 4 months)
- R0 resection
- Absence of distant metastasis or local tumor remnant as defined by a negative post-operative thorax CT and -abdomen CT or MRI and negative (best of DOTA-peptide 68Ga or, FDG) PET imaging if performed preoperatively
- ECOG 0-1
- No prior systemic therapy
Intermediate to high risk of recurrence as defined by the following situations:
- Ki67 ≥ 10% (i.e.: Grade 3 or high Ki67 Grade 2)
- Ki67 5-9% AND (tumor size > 3 cm OR Node positive)
- Ki67 3-5% AND tumor size > 3 cm AND Node positive
- Ki67 < 3% AND tumor size > 3 cm AND Node positive AND (Vascular Emboli OR perineural invasion)
- Age ≥ 18 years at the time of consent, no superior limit
- Adequate bone marrow reserve (hemoglobine > 8 g/dL, absolute neutrophils count ≥ 1500/mm³ and platelets ≥ 80 000/mm³)
- Effective contraception
- Written, dated and signed informed consent by the patient prior to any specific protocol procedure
- Ability to comply with the protocol procedures
- Patient affiliated to a social security system or beneficiary of the same
Exclusion Criteria:
- Poorly differentiated tumours (NEC)
- Mixed NeuroEndocrine Non NeuroEndocrine tumors (MiNEN)
- Neoadjuvant treatment or treatment with chemotherapy regimen used for another malignancy
- Pregnant women or breastfeeding women
- ECOG performance status > 1
- Age < 18 years
- PanNET arising in a genetic syndrome with other NETs already diagnosed (NF1, VHL or MEN)
- History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other treated malignancies with no evidence of disease for at least five years
- Severe renal insufficiency (measured GFR according to MDRD < 30 ml/mn or nephrotic syndrome) or hepatic insufficiency (ALT / AST > 2.5 x ULN or ALT/AST > 5 x ULN if liver function abnormalities are due to the underlying malignancy and/or total serum bilirubin > 2.5 x ULN)
- Serum albumin < 3.0 g/dL unless prothrombin time is within the normal range
- Current treatment with another investigational drug
- Unrecovered toxicity from surgery
- Active or suspected acute or chronic uncontrolled disease that would impart, in the judgment of the Investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the Investigator, would make the patient inappropriate for entry into this study
- Dihydropyrimidine dehydrogenase (DPD) deficiency or not done
- Recent or concomitant treatment with brivudine
- Hypersensitivity to Capecitabine or Temozolomide or to any of the excipients
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Control group
Active surveillance only
|
Active surveillance according to the European Society for Medical Oncology (ESMO) and French Thesaurus National de Cancérologie Digestive (TNCD) guidelines with every 3 months for 2 years, every 4 months for 1 year and then every 6 months for 2 years:
|
|
Expérimental: Experimental group
Adjuvant chemotherapy with Capecitabine-Temozolomide followed by active surveillance
|
Active surveillance according to the European Society for Medical Oncology (ESMO) and French Thesaurus National de Cancérologie Digestive (TNCD) guidelines with every 3 months for 2 years, every 4 months for 1 year and then every 6 months for 2 years:
Chemotherapy with Capecitabine-Temozolomide (per os) for 6 cycles (6 months):
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Disease-free survival (DFS)
Délai: time between randomization and the diagnosis of first recurrence or death, up to 5 years
|
time between randomization and the diagnosis of first recurrence or death, up to 5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Specific survival
Délai: time from randomization to death due to disease progression, toxicity of the treatment or uncontrollable secretory syndrome, up to 5 years
|
time from randomization to death due to disease progression, toxicity of the treatment or uncontrollable secretory syndrome, up to 5 years
|
|
Overall survival
Délai: time from randomization to death from any cause, up to 5 years
|
time from randomization to death from any cause, up to 5 years
|
|
Toxicity assessment
Délai: at baseline, every month during the first year and then every year until the end of the study, up to 5 years
|
at baseline, every month during the first year and then every year until the end of the study, up to 5 years
|
|
Time and pattern of recurrence
Délai: time from randomization to the detection of recurrence, up to 5 years
|
time from randomization to the detection of recurrence, up to 5 years
|
|
Quality of life assessment
Délai: evolution of the scores collected at baseline, every three months during one year, and then every year until the end of the study, up to 5 years
|
evolution of the scores collected at baseline, every three months during one year, and then every year until the end of the study, up to 5 years
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2025-523593-16-00
- 2025 / 4242 (Autre identifiant: Gustave Roussy CSET protocol number)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .